Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial

Author:

Menard Matthew T.1,Farber Alik2,Assmann Susan F.3,Choudhry Niteesh K.4,Conte Michael S.5,Creager Mark A.6,Dake Michael D.7,Jaff Michael R.8,Kaufman John A.9,Powell Richard J.10,Reid Diane M.11,Siami Flora Sandra3,Sopko George11,White Christopher J.12,Rosenfield Kenneth13

Affiliation:

1. Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, MA

2. Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston, MA

3. New England Research Institute, Watertown, MA

4. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA

5. Division of Vascular and Endovascular Surgery, University of California San Francisco Medical Center, San Francisco, CA

6. Dartmouth‐Hitchcock Heart and Vascular Center, Dartmouth‐Hitchcock Medical Center, Lebanon, NH

7. Department of Cardiothoracic Surgery, Stanford Hospital and Clinics, Stanford, CA

8. Fireman Vascular Center, Massachusetts General Hospital, Boston, MA

9. Dotter Interventional Institute/OHSU, Portland, OR

10. Division of Vascular Surgery, Dartmouth‐Hitchcock Medical Center, Lebanon, NH

11. National Heart, Lung and Blood Institute, Bethesda, MD

12. Department of Cardiology, Ochsner Medical Center, New Orleans, LA

13. Division of Cardiology, Massachusetts General Hospital, Boston, MA

Abstract

Background Critical limb ischemia ( CLI ) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence. Methods and Results The Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial is a prospective, randomized, multidisciplinary, controlled, superiority trial designed to compare treatment efficacy, functional outcomes, quality of life, and cost in patients undergoing best endovascular or best open surgical revascularization. Approximately 140 clinical sites in the United States and Canada will enroll 2100 patients with CLI who are candidates for both treatment options. A pragmatic trial design requires consensus on patient eligibility by at least 2 investigators, but leaves the choice of specific procedural strategy within the assigned revascularization approach to the individual treating investigator. Patients with suitable single‐segment of saphenous vein available for potential bypass will be randomized within Cohort 1 (n=1620), while patients without will be randomized within Cohort 2 (n=480). The primary efficacy end point of the trial is Major Adverse Limb Event–Free Survival. Key secondary end points include Re‐intervention and Amputation‐Free‐Survival and Amputation Free‐Survival. Conclusions The BESTCLI trial is the first randomized controlled trial comparing endovascular therapy to open surgical bypass in patients with CLI to be carried out in North America. This landmark comparative effectiveness trial aims to provide Level I data to clarify the appropriate role for both treatment strategies and help define an evidence‐based standard of care for this challenging patient population. Clinical Trial Registration URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 02060630.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3